Cargando…
Effective Treatment of SSTR2-Positive Small Cell Lung Cancer Using (211)At-Containing Targeted α-Particle Therapy Agent Which Promotes Endogenous Antitumor Immune Response
[Image: see text] Small cell lung cancer (SCLC) is a neuroendocrine tumor with a high degree of malignancy. Due to limited treatment options, patients with SCLC have a poor prognosis. We have found, however, that intravenously administered octreotide (Oct) armed with astatine-211 ([(211)At]SAB-Oct)...
Autores principales: | Qin, Shanshan, Yang, Yuanyou, Zhang, Jiajia, Yin, Yuzhen, Liu, Weihao, Zhang, Han, Fan, Xin, Yang, Mengdie, Yu, Fei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2023
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630944/ https://www.ncbi.nlm.nih.gov/pubmed/37788300 http://dx.doi.org/10.1021/acs.molpharmaceut.3c00427 |
Ejemplares similares
-
Alpha radionuclide-chelated radioimmunotherapy promoters enable local radiotherapy/chemodynamic therapy to discourage cancer progression
por: Zhang, Jiajia, et al.
Publicado: (2022) -
Construction and Preclinical Evaluation of (211)At Labeled Anti-mesothelin Antibodies as Potential Targeted Alpha Therapy Drugs
por: Wang, Xudong, et al.
Publicado: (2020) -
mRNA expression of somatostatin receptor subtypes SSTR-2, SSTR-3, and SSTR-5 and its significance in pancreatic cancer
por: Shahbaz, Muhammad, et al.
Publicado: (2015) -
The effect of strength and endurance training on SSTR2 and SSTR5 in patients with colorectal cancer
por: Zanjani, Farhad Safari, et al.
Publicado: (2019) -
Expression of Somatostatin Receptor Subtypes (SSTR-1–SSTR-5) in Pediatric Hematological and Oncological Disorders
por: Harda, Kristof, et al.
Publicado: (2020)